HDL and Atherosclerosis

High-Density Lipoproteins: From Basic Biology to Clinical Aspects

Volumn , Issue , 2008, Pages 491-505

  Barter, Philip J ^a   Rye, Kerry Anne ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Atherosclerosis; Clinical aspects of HDL; HDL subpopulations; High density lipoproteins; Potential antiatherogenic properties

Indexed keywords

EID: 84878584548     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527625178.ch20     Document Type: Chapter

References (76)

1. Gordon, D. J., Knoke, J., Probstfield, J. L., Superko, R., Tyroler, H. A. (1986) High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation, 74, 1217-1225.
2. Enger, S. C., Hjermann, I., Foss, O. P., Helgeland, A., Holme, I., Leren, P., Norum, K. R. (1979) High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective casecontrol study in middle-aged men of the Oslo study. Artery., 5, 170-181.
3. Miller, N. E., Thelle, D. S., Forde, O. H., Mjos, O. D. (1977) The Tromso heart-study. High-density lipoprotein and coronary heartdisease: a prospective case-control study. Lancet., 1, 965-968.
4. Miller, M., Seidler, A., Kwiterovich, P. O., Pearson, T. A. (1992) Longterm predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation, 86, 1165-1170.
5. Pekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., Tyroler, H. A. (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J. Med., 322, 1700-1707.
6. Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Jr., Bangdiwala, S., Tyroler, H. A. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79, 8-15.
7. Jacobs, D. R., Jr., Mebane, I. L., Bangdiwala, S. I., Criqui, M. H., Tyroler, H. A. (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J. Epidemiol., 131, 32-47.
8. Pedersen, T. R., Olsson, A. G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyorala, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A., Cook, T. J. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453-1460.
9. Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., Furberg, C. D. (2000) Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation, 102, 1893-1900.
10. Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A., Hague, W., Keech, A., Thompson, P., White, H., Shaw, J., Tonkin, A. (2002) Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105, 1162-1169.
11. Badimon, J. J., Badimon, L., Fuster, V. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest., 85, 1234-1241.
12. Paszty, C., Maeda, N., Verstuyft, J., Rubin, E. M. (1994) Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest., 94, 899-903.
13. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., Clift, S. M. (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature, 353, 265-267.
14. Plump, A. S., Scott, C. J., Breslow, J. L. (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A., 91, 9607-9611.
15. Austin, M. A. (1991) Plasma triglyceride and coronary heart disease. Arterioscler. Thromb., 11, 2-14.
16. Despres, J. P., Moorjani, S., Ferland, M., Tremblay, A., Lupien, P. J., Nadeau, A., Pinault, S., Theriault, G., Bouchard, C. (1989) Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis, 9, 203-210.
17. Haffner, S. M., Valdez, R. A., Hazuda, H. P., Mitchell, B. D., Morales, P. A., Stern, M. P. (1992) Prospective analysis of the insulinresistance syndrome (syndrome X). Diabetes, 41, 715-722.
18. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., Dawber, T. R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62, 707-714.
19. Duffy, D. and Rader, D. J. (2006) Emerging therapies targeting highdensity lipoprotein metabolism and reverse cholesterol transport. Circulation, 113, 1140-1150.
20. Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A., Rubin, A. L. (1993) In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. U.S.A., 90, 12040-12044.
21. Seetharam, D., Mineo, C., Gormley, A. K., Gibson, L. L., Vongpatanasin, W., Chambliss, K. L., Hahner, L. D., Cummings, M. L., Kitchens, R. L., Marcel, Y. L., Rader, D. J., Shaul, P. W. (2006) High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res., 98, 63-72.
22. Tso, C., Martinic, G., Fan, W. H., Rogers, C., Rye, K. A., Barter, P. J. (2006) High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol., 26, 1144-1149.
23. Sugatani, J., Miwa, M., Komiyama, Y., Ito, S. (1996) High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J. Lipid Mediat. Cell Signal., 13, 73-88.
24. Mineo, C., Deguchi, H., Griffin, J. H., Shaul, P. W. (2006) Endothelial and antithrombotic actions of HDL. Circ. Res., 98, 1352-1364.
25. Bisoendial, R. J., Hovingh, G. K., Levels, J. H., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J., Stroes, E. S. (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation, 107, 2944-2948.
26. Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M., Navab, M., Fogelman, A. M. (2004) Antiinflammatory properties of HDL. Circ. Res., 95, 764-772.
27. Yancey, P. G., Bortnick, A. E., Kellner-Weibel, G., de la Llera-Moya, M., Phillips, M. C., Rothblat, G. H. (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol., 23, 712-719.
28. Yokoyama, S. (2006) ABCA1 and biogenesis of HDL. J. Atheroscler. Thromb., 13, 1-15.
29. Wang, N., Lan, D., Chen, W., Matsuura, F., Tall, A. R. (2004) ATPbinding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A., 101, 9774-9779.
30. Nakamura, K., Kennedy, M. A., Baldan, A., Bojanic, D. D., Lyons, K., Edwards, P. A. (2004) Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J. Biol. Chem., 279, 45980-45989.
31. Mackness, M. I., Durrington, P. N., Mackness, B. (2004) The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am. J. Cardiovasc. Drugs, 4, 211-217.
32. Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., Laks, H. et al. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest., 88, 2039-2046.
33. Suc, I., Escargueil-Blanc, I., Troly, M., Salvayre, R., Negre-Salvayre, A. (1997) HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol., 17, 2158-2166.
34. Maier, J. A., Barenghi, L., Pagani, F., Bradamante, S., Comi, P., Ragnotti, G. (1994) The protective role of highdensity lipoprotein on oxidized-lowdensity-lipoprotein-induced U937/endothelial cell interactions. Eur. J. Biochem., 221, 35-41.
35. Mackness, M. I. and Durrington, P. N. (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 115, 243-253.
36. Garner, B., Witting, P. K., Waldeck, A. R., Christison, J. K., Raftery, M., Stocker, R. (1998) Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J. Biol. Chem., 273, 6080-6087.
37. Cockerill, G. W., Rye, K. A., Gamble, J. R., Vadas, M. A., Barter, P. J. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol., 15, 1987-1994.
38. Xia, P., Vadas, M. A., Rye, K. A., Barter, P. J., Gamble, J. R. (1999) High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem., 274, 33143-33147.
39. Baker, P. W., Rye, K. A., Gamble, J. R., Vadas, M. A., Barter, P. J. (1999) Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res., 40, 345-353.
40. Baker, P. W., Rye, K. A., Gamble, J. R., Vadas, M. A., Barter, P. J. (2000) Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res., 41, 1261-1267.
41. Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., Laks, H., Fogelman, A. M. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest., 88, 2039-2046.
42. Moudry, R., Spycher, M. O., Doran, J. E. (1997) Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock., 7, 175-181.
43. Dimayuga, P., Zhu, J., Oguchi, S., Chyu, K-Y., Xu, X-O.H., Yano, J., Shah, P. K., Nilsson, J., Cercek, B. (1999) Reconstituted HDL containing human apolipoprotein A-I reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Comm., 264, 465-468.
44. Rong, J. X., Li, J., Reis, E. D., Choudhury, R. P., Dansky, H. M., Elmalem, V. I., Fallon, J. T., Breslow, J. L., Fisher, E. A. (2001) Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation, 104, 2447-2452.
45. Nicholls, S. J., Cutri, B., Worthley, S. G., Kee, P., Rye, K. A., Bao, S., Barter, P. J. (2005) Impact of shortterm administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol., 25, 2416-2421.
46. Cockerill, G. W., Huehns, T. Y., Weerasinghe, A., Stocker, C., Lerch, P. G., Miller, N. E., Haskard, D. O. (2001) Elevation of plasma highdensity lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 103, 108-112.
47. Paterno, R., Ruocco, A., Postiglione, A., Hubsch, A., Anderson, I., Lang, M. G. (2004) Reconstituted highdensity lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc. Dis., 17, 204-211.
48. Cockerill, G. W., McDonald, M. C., Mota-Filipe, H., Cuzzocrea, S., Miller, N. E., Thiemermann, C. (2001) High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. Faseb J., 15, 1941-1952.
49. Nicholls, S. J., Dusting, G. J., Cutri, B., Bao, S., Drummond, G. R., Rye, K. A., Barter, P. J. (2005) Reconstituted high-density lipoproteins inhibit the acute prooxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation, 111, 1543-1550.
50. Spieker, L. E., Sudano, I., Hurlimann, D., Lerch, P. G., Lang, M. G., Binggeli, C., Corti, R., Ruschitzka, F., Luscher, T. F., Noll, G. (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation, 105, 1399-1402.
51. Bisoendial, R. J., Hovingh, G. K., Levels, J. H. M., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G. (2003) Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. Circulation, 107, 2944-2948.
52. Rye, K. A., Clay, M. A., Barter, P. J. (1999) Remodelling of high density lipoproteins by plasma factors. Atherosclerosis, 145, 227-238.
53. Warden, C. H., Hedrick, C. C., Qiao, J. H., Castellani, L. W., Lusis, A. J. (1993) Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science, 261, 469-472.
54. Amouyel, P., Isorez, D., Bard, J. M., Goldman, M., Lebel, P., Zylberberg, G., Fruchart, J. C. (1993) Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler. Thromb., 13, 1640-1644.
55. Tailleux, A., Bouly, M., Luc, G., Castro, G., Caillaud, J. M., Hennuyer, N., Poulain, P., Fruchart, J. C., Duverger, N., Fievet, C. (2000) Decreased susceptibility to dietinduced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler. Thromb. Vas.c Biol., 20, 2453-2458.
56. Miller, N. E. (1987) Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J., 113, 589-597.
57. Chiesa, G., Monteggia, E., Marchesi, M., Lorenzon, P., Laucello, M., Lorusso, V., Di Mario, C., Karvouni, E., Newton, R. S., Bisgaier, C. L., Franceschini, G., Sirtori, C. R. (2002) Recombinant apolipoprotein A-I (Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res., 90, 974-980.
58. Duverger, N., Kruth, H., Emmanuel, F., Caillaud, J. M., Viglietta, C., Castro, G., Tailleux, A., Fievet, C., Fruchart, J. C., Houdebine, L. M., Denefle, P. (1996) Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation, 94, 713-717.
59. Hoeg, J. M., Santamarina-Fojo, S., Berard, A. M., Cornhill, J. F., Herderick, E. E., Feldman, S. H., Haudenschild, C. C., Vaisman, B. L., Hoyt, R. F., Jr., Demosky, S. J., Jr., Kauffman, R. D., Hazel, C. M., Marcovina, S. M., Brewer, H. B., Jr. (1996) Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents dietinduced atherosclerosis. Proc. Natl. Acad. Sci. U.S.A., 93, 11448-11453.
60. Berard, A. M., Foger, B., Remaley, A., Shamburek, R., Vaisman, B. L., Talley, G., Paigen, B., Hoyt, R. F., Jr., Marcovina, S., Brewer, H. B., Jr., Santamarina-Fojo, S. (1997) High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med., 3, 744-749.
61. Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., Mizushima, A. (1998) Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem., 273, 5033-5036.
62. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., Shinkai, H. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature, 406, 203-207.
63. The Lipid Research Clinics Coronary Primary Prevention Trial results, (1984) I. Reduction in incidence of coronary heart disease. Jama., 251, 351-364.
64. Gotto, A. M., Jr., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendorfer, A., Beere, P. A., Watson, D. J., Downs, J. R., de Cani, J. S. (2000) Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation, 101, 477-484.
65. (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97, 1440-1445.
66. Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J. K., Manttari, M., Heinonen, O. P., Frick, M. H. (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 85, 37-45.
67. Tenkanen, L., Manttari, M., Manninen, V. (1995) Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation, 92, 1779-1785.
68. Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., Wittes, J. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 341, 410-418.
69. Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., Rubins, H. B. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. Jama., 285, 1585-1591.
70. (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 102, 21-27.
71. Tenenbaum, A., Motro, M., Fisman, E. Z., Tanne, D., Boyko, V., Behar, S. (2005) Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med., 165, 1154-1160.
72. Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., Forder, P., Pillai, A., Davis, T., Glasziou, P., Drury, P., Kesaniemi, Y. A., Sullivan, D., Hunt, D., Colman, P., d'Emden, M., Whiting, M., Ehnholm, C., Laakso, M. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 366, 1849-1861.
73. Carlson, L. A. (2004) Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broadspectrum lipid drug. Int. J. Clin. Pract., 58, 706-713.
74. Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J. T., Kaplan, C., Zhao, X. Q., Bisson, B. D., Fitzpatrick, V. F., Dodge, H. T. (1990) Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med., 323, 1289-1298.
75. Brown, B. G., Zhao, X. Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., Frohlich, J., Albers, J. J. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 345, 1583-1592.
76. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., Halpern, S., Crowe, T., Blankenship, J. C., Kerensky, R. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama., 290, 2292-2300.